October 13, 2017 / 11:38 AM / 2 months ago

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

Oct 13 (Reuters) - Miragen Therapeutics Inc

* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting

* Miragen Therapeutics Inc - ‍MRG-106 has been well-tolerated at all dose levels evaluated to date​

* Miragen Therapeutics Inc - ‍MRG-106 has been generally well-tolerated for all 27 patients evaluated to date at dose levels ranging from 75 mg to 900 mg​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below